Description: AIDA Pharmaceuticals, Inc., located in Hangzhou, the People’s Republic of China, operates through its subsidiaries, which include Earjoy Group Limited (Earjoy), Hangzhou Aida Pharmaceutical Co., Ltd (Hangzhou Aida), Hangzhou Boda Medical Research and Development Co., Ltd. (Boda), Hainan Aike Pharmaceutical Co., Ltd. (Aike), Changzhou Fangyuan Pharmaceutical Co., Ltd. (Fangyuan) and Shanghai Qiaer Bio-technology Co., Ltd (Qiaer). Earjoy is an investment holding company. Hangzhou Aida is a pharmaceutical company engaged in the development, manufacture, marketing, licensing, and distribution of pharmaceutical products primarily in mainland China. Hangzhou Aida has a total of nine production lines for the manufacture of antibiotics, cardiovascular and anti-tumor drugs in various forms, including injectable powder, injectable liquid, capsules, tablets and ointments. Hangzhou Aida’s primary product is the injectable powder form of Etimicin Sulfate.
31 Dingjiang Road
Hangzhou,
310016
China
Phone:
86 571 8580 2712
Officers
| Name | Title |
|---|---|
| Mr. Biao Jin | Chairman and Chief Exec. Officer |
| Ms. Lin Hui | Chief Financial Officer and Principal Accounting Officer |
| Mr. Yue Jun Jiang | Chief of Investment Department and Sec. |
| Mr. Qiu Jiajun | Member of Compensation Committee and Director |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7672 |
| Price-to-Sales TTM: | 0.2066 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 450 |